Abstract
Cardiovascular diseases (CVD), primarily inflammatory cardiomyopathy, are characterized by the infiltration of inflammatory cells into the myocardium. It has a relatively high risk of deteriorating heart function and has heterogeneous etiologies. Inflammatory cardiomyopathy is mainly mediated by viral infections but can also be mediated by protozoa, fungal or bacterial infections. Besides that, there are a wide variety of drugs, toxic substances, and systemic immune-mediated diseases that result in the development of cardiovascular diseases (CVDs). Despite broad research, inflammatory cardiomyopathy has a poor prognosis. The roles of the pathogens, host genomic counterparts and environmental triggers in the progression of disease are still under consideration, including the role of some viruses as active inducers and others as bystanders. In this review article, we review the available evidence on the types, pathogenesis and treatment of myocarditis, inflammatory cardiomyopathy, and atherosclerosis with a particular focus on virus-associated cardiac diseases.
Keywords: COVID-19, cardiovirus, echovirus, coxsackievirus, cytomegalovirus, HSV-1 and 2, parvovirus B19, hepatitis viruses, influenza viruses.
Current Pharmaceutical Design
Title:Association of Viruses in the Development of Cardiovascular Diseases
Volume: 27 Issue: 37
Author(s): Bisma Rauff *, Arif Malik, Yasir A. Bhatti , Shafiq A. Chudhary, Kaneez Fatima, Shafquat Rafiq , Aisha Tahir, Sumaira Sharif and Ishtiaq Qadri
Affiliation:
- Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW Sydney,Australia
Keywords: COVID-19, cardiovirus, echovirus, coxsackievirus, cytomegalovirus, HSV-1 and 2, parvovirus B19, hepatitis viruses, influenza viruses.
Abstract: Cardiovascular diseases (CVD), primarily inflammatory cardiomyopathy, are characterized by the infiltration of inflammatory cells into the myocardium. It has a relatively high risk of deteriorating heart function and has heterogeneous etiologies. Inflammatory cardiomyopathy is mainly mediated by viral infections but can also be mediated by protozoa, fungal or bacterial infections. Besides that, there are a wide variety of drugs, toxic substances, and systemic immune-mediated diseases that result in the development of cardiovascular diseases (CVDs). Despite broad research, inflammatory cardiomyopathy has a poor prognosis. The roles of the pathogens, host genomic counterparts and environmental triggers in the progression of disease are still under consideration, including the role of some viruses as active inducers and others as bystanders. In this review article, we review the available evidence on the types, pathogenesis and treatment of myocarditis, inflammatory cardiomyopathy, and atherosclerosis with a particular focus on virus-associated cardiac diseases.
Export Options
About this article
Cite this article as:
Rauff Bisma *, Malik Arif , Bhatti A. Yasir, Chudhary A. Shafiq , Fatima Kaneez , Rafiq Shafquat , Tahir Aisha , Sharif Sumaira and Qadri Ishtiaq , Association of Viruses in the Development of Cardiovascular Diseases, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612827666210426094502
DOI https://dx.doi.org/10.2174/1381612827666210426094502 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Notch Signaling in Cardiovascular Disease and Calcification
Current Cardiology Reviews Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Studies on Nonsense Mediated Decay Reveal Novel Therapeutic Options for Genetic Diseases
Recent Patents on DNA & Gene Sequences Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews Current Genomics in Cardiovascular Medicine
Current Genomics Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Cardiac Multidetector Computed Tomography: Basic Physics of Image Acquisition and Clinical Applications
Current Cardiology Reviews Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Climate Change, Climate Variability and Brucellosis
Recent Patents on Anti-Infective Drug Discovery Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Pleiotropic Effects of ARB in Vascular Metabolism - Focusing on Atherosclerosis-Based Cardiovascular Disease
Current Vascular Pharmacology